MXPA03004172A - Kit de tratamiento para coadyuvar con la antibioticoterapia en enfermedades infecciosas intracelulares. - Google Patents

Kit de tratamiento para coadyuvar con la antibioticoterapia en enfermedades infecciosas intracelulares.

Info

Publication number
MXPA03004172A
MXPA03004172A MXPA03004172A MXPA03004172A MXPA03004172A MX PA03004172 A MXPA03004172 A MX PA03004172A MX PA03004172 A MXPA03004172 A MX PA03004172A MX PA03004172 A MXPA03004172 A MX PA03004172A MX PA03004172 A MXPA03004172 A MX PA03004172A
Authority
MX
Mexico
Prior art keywords
infectious diseases
assists
type
treatment kit
antibiotic therapy
Prior art date
Application number
MXPA03004172A
Other languages
English (en)
Inventor
Lopez Casillas Fernando
Original Assignee
Univ Mexico Nacional Autonoma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Mexico Nacional Autonoma filed Critical Univ Mexico Nacional Autonoma
Priority to MXPA03004172A priority Critical patent/MXPA03004172A/es
Priority to EP04732521A priority patent/EP1623714A4/en
Priority to JP2006532111A priority patent/JP2007500207A/ja
Priority to PCT/MX2004/000031 priority patent/WO2004100864A2/es
Priority to US10/556,376 priority patent/US8840892B2/en
Publication of MXPA03004172A publication Critical patent/MXPA03004172A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

La presente invencion describe el uso de inmunomoduladores para apoyar el tratamiento habitual contra enfermedades infecciosas ocasionadas por organismos intracelulares facultativos. Partiendo del analisis de la respuesta inmunologica que se instala en este tipo de infecciones, particularmente la ocasionada por la Tuberculosis, se utiliza un kit de tratamiento que asocia un inmunomodulador del tipo betaglicano soluble, asociado con un agente anti inflamatorio del tipo de bloqueadores de la prostaglandina E que al usarlos conjuntamente modulan la respuesta inmunologica permitiendo que se acorte el tiempo de tratamiento con los antibioticos respectivos.
MXPA03004172A 2003-05-13 2003-05-13 Kit de tratamiento para coadyuvar con la antibioticoterapia en enfermedades infecciosas intracelulares. MXPA03004172A (es)

Priority Applications (5)

Application Number Priority Date Filing Date Title
MXPA03004172A MXPA03004172A (es) 2003-05-13 2003-05-13 Kit de tratamiento para coadyuvar con la antibioticoterapia en enfermedades infecciosas intracelulares.
EP04732521A EP1623714A4 (en) 2003-05-13 2004-05-12 TREATMENT KIT USED IN CONJUNCTION WITH ANTIBIO THERAPY FOR THE TREATMENT OF INTRACELLULAR INFECTIOUS DISEASES
JP2006532111A JP2007500207A (ja) 2003-05-13 2004-05-12 細胞内感染性疾患の抗生物質治療を助ける治療用キット
PCT/MX2004/000031 WO2004100864A2 (es) 2003-05-13 2004-05-12 Kit de tratamiento para coadyuvar con la antibioticoterapia en enfermedades infecciosas intracelulares
US10/556,376 US8840892B2 (en) 2003-05-13 2004-05-12 Method of administering antibiotic therapy for treating intracellular infectious diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MXPA03004172A MXPA03004172A (es) 2003-05-13 2003-05-13 Kit de tratamiento para coadyuvar con la antibioticoterapia en enfermedades infecciosas intracelulares.

Publications (1)

Publication Number Publication Date
MXPA03004172A true MXPA03004172A (es) 2004-11-18

Family

ID=33448397

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03004172A MXPA03004172A (es) 2003-05-13 2003-05-13 Kit de tratamiento para coadyuvar con la antibioticoterapia en enfermedades infecciosas intracelulares.

Country Status (5)

Country Link
US (1) US8840892B2 (es)
EP (1) EP1623714A4 (es)
JP (1) JP2007500207A (es)
MX (1) MXPA03004172A (es)
WO (1) WO2004100864A2 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010215A1 (en) * 1991-11-15 1993-05-27 Memorial Sloan-Kettering Cancer Center Purified proteoglycan betaglycan, compositions, and methods
WO1995010610A1 (en) * 1993-10-15 1995-04-20 La Jolla Cancer Research Foundation BETAGLYCAN POLYPEPTIDES HAVING TGF-β BINDING ACTIVITY
EP0889954A1 (en) * 1996-09-03 1999-01-13 Health Research, Inc. Treatment of antigen presenting cells to modulate antigen presenting cell function
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
WO2001043763A1 (en) * 1999-12-15 2001-06-21 Research Development Foundation Betaglycan as an inhibin receptor and uses thereof

Also Published As

Publication number Publication date
EP1623714A2 (en) 2006-02-08
WO2004100864A2 (es) 2004-11-25
JP2007500207A (ja) 2007-01-11
EP1623714A4 (en) 2009-07-22
WO2004100864A3 (es) 2005-12-15
US8840892B2 (en) 2014-09-23
US20060251657A1 (en) 2006-11-09

Similar Documents

Publication Publication Date Title
MY137757A (en) Therapeutic treatment
EA200600620A1 (ru) Набор для ингаляции с ингаляционным порошком, содержащим тиотропий
EP1791958A4 (en) YEAST / BACTERIA-TWO-HYBRID SYSTEM AND METHOD OF APPLICATION THEREOF
ATE461217T1 (de) Glp-1-verbindungen
NO20053042L (no) Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi.
UA94221C2 (en) Lipocalin protein
EP1740183B8 (en) Novel use for pde5 inhibitors
BRPI0417823A (pt) métodos para uso de bifidobactérias probióticas para animais de estimação
BRPI0417825A (pt) métodos para uso de lactobacilli probióticos para animais de estimação
EP1670450B8 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
ZA202105285B (en) Antibody against human il-4ra and use thereof
MX2008007808A (es) Analogos de rifamicina y usos de ellos.
NZ577393A (en) Use of 3-alpha-androstanediol, optionally in combination with a pde5 inhibitor, in the treatment of sexual dysfunction
MX2007002277A (es) Metodos para formar retinoides y usos de los mismos.
HRP20090513T1 (en) S-mirtazapine for the treatment of hot flush
HK1106253A1 (en) Desoxo-nonadepsipeptides
ZA200703441B (en) Coadministration of tigecycline and digoxin
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
WO2003094367A3 (en) Improved first aid kit instructions
MXPA03004172A (es) Kit de tratamiento para coadyuvar con la antibioticoterapia en enfermedades infecciosas intracelulares.
DE50309647D1 (de) Ng fibrotischer erkrankungen
MY140194A (en) Novel fusidic acid derivatives
WO2003096987A9 (en) Methods of use and compositions for the diagnosis and treatment of infectious disease
UA27643U (en) Method for treatment of community-acquired pneumonia in children
DK1776366T3 (da) Immunomodulerende oxopyrazolocinnoliner som CD80-inhibitorer

Legal Events

Date Code Title Description
FG Grant or registration